|
Name |
Zelkovamycin
|
| Molecular Formula | C36H45N9O9S | |
| IUPAC Name* |
(16Z)-7-acetyl-13-ethyl-16-ethylidene-4-[(7-methoxy-1H-indol-3-yl)methyl]-7,18,22-trimethyl-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone
|
|
| SMILES |
CCC1C(=O)N/C(=C\C)/C(=O)N(CC(=O)NC(C2=NC(=CS2)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N1)(C)C(=O)C)CC3=CNC4=C3C=CC=C4OC)C)C
|
|
| InChI |
InChI=1S/C36H45N9O9S/c1-8-22-30(49)41-23(9-2)34(52)45(6)16-28(48)39-18(3)33-43-25(17-55-33)31(50)42-24(13-20-14-37-29-21(20)11-10-12-26(29)54-7)32(51)44-36(5,19(4)46)35(53)38-15-27(47)40-22/h9-12,14,17-18,22,24,37H,8,13,15-16H2,1-7H3,(H,38,53)(H,39,48)(H,40,47)(H,41,49)(H,42,50)(H,44,51)/b23-9-
|
|
| InChIKey |
VYMRECQGDKKGCJ-AQHIEDMUSA-N
|
|
| Synonyms |
Zelkovamycin; 221197-33-7; (12Z,16Z)-7-acetyl-13-ethyl-16-ethylidene-4-((7-methoxy-1H-indol-3-yl)methyl)-7,18,22-trimethyl-3,6,9,12,15,18,21-heptaaza-1(2,4)-thiazolacyclodocosaphane-2,5,8,11,14,17,20-heptaone; Zelcovamycin; (16Z)-7-acetyl-13-ethyl-16-ethylidene-4-[(7-methoxy-1H-indol-3-yl)methyl]-7,18,22-trimethyl-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone
|
|
| CAS | NA | |
| PubChem CID | 10395445 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 779.9 | ALogp: | 0.9 |
| HBD: | 7 | HBA: | 11 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 278.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 55 | QED Weighted: | 0.14 |
| Caco-2 Permeability: | -5.793 | MDCK Permeability: | 0.00000359 |
| Pgp-inhibitor: | 0.76 | Pgp-substrate: | 1 |
| Human Intestinal Absorption (HIA): | 0.853 | 20% Bioavailability (F20%): | 0.955 |
| 30% Bioavailability (F30%): | 0.991 |
| Blood-Brain-Barrier Penetration (BBB): | 0.066 | Plasma Protein Binding (PPB): | 75.36% |
| Volume Distribution (VD): | 0.228 | Fu: | 38.60% |
| CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.112 |
| CYP2C19-inhibitor: | 0.134 | CYP2C19-substrate: | 0.049 |
| CYP2C9-inhibitor: | 0.303 | CYP2C9-substrate: | 0.442 |
| CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.113 |
| CYP3A4-inhibitor: | 0.261 | CYP3A4-substrate: | 0.45 |
| Clearance (CL): | 2.481 | Half-life (T1/2): | 0.721 |
| hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.687 |
| Drug-inuced Liver Injury (DILI): | 0.822 | AMES Toxicity: | 0.006 |
| Rat Oral Acute Toxicity: | 0.674 | Maximum Recommended Daily Dose: | 0.486 |
| Skin Sensitization: | 0.063 | Carcinogencity: | 0.008 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.002 |
| Respiratory Toxicity: | 0.028 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004435 | ![]() |
0.825 | D09ZIO | ![]() |
0.298 | ||
| ENC004434 | ![]() |
0.822 | D0X9PF | ![]() |
0.256 | ||
| ENC004432 | ![]() |
0.819 | D0M2YE | ![]() |
0.237 | ||
| ENC004433 | ![]() |
0.702 | D0L7LC | ![]() |
0.234 | ||
| ENC005139 | ![]() |
0.341 | D07DSQ | ![]() |
0.233 | ||
| ENC005343 | ![]() |
0.317 | D00TLP | ![]() |
0.229 | ||
| ENC001987 | ![]() |
0.307 | D02XIY | ![]() |
0.229 | ||
| ENC002515 | ![]() |
0.297 | D0E2OU | ![]() |
0.220 | ||
| ENC005563 | ![]() |
0.295 | D0D8XY | ![]() |
0.213 | ||
| ENC005276 | ![]() |
0.294 | D07ESC | ![]() |
0.209 | ||